市場調查報告書

數位療法的全球市場

Digital Therapeutics

出版商 Global Industry Analysts, Inc. 商品編碼 903083
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
數位療法的全球市場 Digital Therapeutics
出版日期: 2020年09月01日內容資訊: 英文 205 Pages
簡介

本報告提供全球數位療法市場調查,提供市場概要,各市場區隔·地區的市場規模的變化與預測,市場趨勢及成長要素分析,競爭情形,主要企業的簡介等全面性資訊。

第1章 調查手法

第2章 摘要整理

  • 市場概要
    • 競爭企業的市場佔有率
    • 競爭企業的市場佔有率:方案
  • 關注企業
  • 市場趨勢和成長要素
  • 全球市場預測

第3章 市場分析

  • 地區市場分析
  • 美國
    • 概要
    • 企業的市場佔有率
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 其他歐洲各國
  • 亞太地區
  • 其他地區

第4章 競爭情形

  • 2MORROW, INC.
  • CANARY HEALTH
  • GINGER.IO
  • LIVONGO HEALTH
  • MANGO HEALTH
  • NOOM INC.
  • OMADA HEALTH, INC.
  • PROPELLER HEALTH
  • PROTEUS DIGITAL HEALTH, INC.
  • WELLDOC

第5章 調查資料

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP11567

The global market for Digital Therapeutics (DTx) is projected to reach US$1.0 billion by 2025 driven by strong adoption of digital platforms like smartphones, apps, electronic wearables, mobile internet; growing focus on value based care; and rising venture capital investments in digital health based business models. DTx involves the use of online technology platforms such as mHealth tools; medical sensors; electronic medical wearables; artificial intelligence (IT); telehealth & wireless communication platforms; smartphones, apps and mobile internet, to offer medical care. The goal of DTx is to induce behavioral and lifestyle changes that positively influence disease treatment outcomes. Benefits of digital therapeutics driving its importance in the healthcare industry include the promise of overcoming the limitation of current primary care by providing timely and proactive care, reducing the risk of disease progression and lowering the burden on emergency care; enables continuous remote patient monitoring; provides social support and guidance; enables implementation of preventive healthcare; ensures patient empowerment as it encourages treatment plans based on self-reported data like diet and other lifestyle factors; greater accountability of care givers; continued support in between doctor visits; and improved treatment outcome.

Healthcare reforms and the ensuing migration to value based care will provide the Launchpad for increased acceptance, adoption and proliferation of DTx, as the technology has the potential to reduce healthcare costs while simultaneously increase efficiency. Key features that make DTx a natural fit for value based care include cost of DTx which is significantly lower than traditional medicine; patient centric continuum of care; use of outcome oriented and evidence based therapeutic solutions; elimination of wasteful healthcare expenditure as timely care reduces the need for diagnostic and intensive drug interventions; lower consumption of hospital resources as it reduces the pressure on an already overburdened emergence care; better use of patient engagement that encourages self-management of diseases; and use of real-time actionable insights that help optimize care delivery decisions. Digital solutions which are emerging as effective therapy tools include electronic CBT (cognitive behavioral therapy); virtual therapy guidance and counselling that include web therapy, phone therapy, text therapy or online therapy; therapy support applications that educate and offer advice on coping strategies, relaxation techniques, medication reminders and references to nearby treatment programs to ensure accessibility; and telediagnosis/remote diagnostics. Of special note is the hidden and the yet untapped value in the "Medicine as a Service" business model that brings even pharmaceutical companies into the value based care loop. Faced with competition and profitability pressures, drug companies are entering into the DTx space as powerful ecosystem players backed with financial resources to offer services that improve access and adherence to prescription drugs for chronic conditions. Powered by the dynamics of cloud computing "Medicine as a Service" pushes patients into the center of business strategies of drug companies.

As the healthcare community seeks to cost-effectively tackle the growing economic and financial burden of chronic diseases such as diabetes, hypertension and cardiovascular diseases, DTx will emerge as the way forward in healthcare. As the number of people living with diseases increase, healthcare strategies should evolve beyond just the pill to a continuous care plan that include staying informed and engaged. The biggest impact of DTx is in the field of mental health as it offers a novel therapy platform for this hugely unmet medical field. Gamification in mental health apps is the newest mhealth tool for positive behavioral reinforcement and to promote patient engagement. Telepsychiatry using videoconferencing and telemedicine eliminates the stigma associated with psychiatric care by offering patients discreet ways to receive medication management care and timely psychiatric evaluations. The United States and Europe represent large markets worldwide with a combined share of 84.4% of the global market. The United States also ranks as the fastest growing market with a CAGR of 27.8% over the analysis period supported by well-developed digital infrastructure that provides the foundation for DTx. The country also spearheads the global commitment towards value-based care and outcome-based healthcare with robust financial incentives that encourage value-based care and disincentives that penalize and prevent wasteful healthcare spending among hospitals.

Competitors identified in this market include, among others,

  • Canary Health, Inc.
  • Dthera Sciences
  • Fitbit Health Solutions
  • Livongo Health, Inc.
  • Medtronic, Plc
  • Omada Health, Inc.
  • Propeller Health
  • Pear Therapeutics, Inc.
  • Proteus Digital Health, Inc.
  • WellDoc, Inc.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Digital Therapeutics: An Introduction
    • Outlook
    • Leading Markets
    • Factors Impeding Growth
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Canary Health, Inc. (USA)
    • Dthera Sciences (USA)
    • Fitbit Health Solutions (USA
    • Livongo Health, Inc. (USA)
    • Medtronic, Plc (Ireland)
    • Omada Health, Inc. (USA)
    • Propeller Health (USA)
    • Pear Therapeutics, Inc. (USA)
    • Proteus Digital Health, Inc. (USA)
    • WellDoc, Inc. (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Digital Therapeutics Continue to Attract Venture Capital Investments
    • Total Venture Capital Funding and Number of Deals in Digital Health Space: 2011-2018
    • Digital Health Funding by Segment (in US$ Million): 9M 2019
    • Startups Flock the Digital Therapeutics Market
    • Select Digital Therapeutics Startups
    • Digital Health Unicorn Startups
    • Quarterly Investments by Digital Therapeutics Startups in US$ Million: Q1 2018 to Q2 2019
    • Pipeline Products Drive Growth Prospects
    • A Snapshot of Select DTx Pipeline Products
    • Pharma Majors Foray into Uncharted Territory
    • Pharmaceutical Companies Team Up with Payers to Seek Reimbursement
    • Growing Focus on Preventative Healthcare Widens Growth Opportunities
    • Overcoming the Stigma of Mental Health through Digital Therapeutics
    • Global Number of People Suffering from Mental Disorders (In Million)
    • Growing Prevalence of Chronic Diseases to Boost Market Growth
    • Worldwide Prevalence of Diabetes: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Global Annual Medical Cost of CVD in US$ Billion (2010-2030)
    • Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025
    • Digital Therpeutics in Oncology
    • Proliferation of Smart Devices Bodes Well for Market Growth
    • Smartphone Penetration (as a Proportion of Total Mobile Users) by Region for the Years 2018 and 2025
    • United States Mobile Health Apps Market by Type (in %): 2018 & 2025
    • Growing Focus on Reducing Healthcare Costs Bolsters Market Growth
    • Global Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, and 2022
    • Aging Population and their Vulnerability to Various Health Conditions: A Vital Growth Driver
    • Global Population for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Digital Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 2: World 7-Year Perspective for Digital Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Preventive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 4: World 7-Year Perspective for Preventive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Treatment/Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 6: World 7-Year Perspective for Treatment/Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for B2C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 8: World 7-Year Perspective for B2C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for B2B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 10: World 7-Year Perspective for B2B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • TABLE 11: USA Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 12: USA 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 13: USA Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 14: USA 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • CANADA
    • TABLE 15: Canada Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 16: Canada 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 17: Canada Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 18: Canada 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 20: Japan 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 21: Japan Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 22: Japan 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • CHINA
    • TABLE 23: China Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 24: China 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 25: China Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 26: China 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • EUROPE
    • TABLE 27: Europe Current & Future Analysis for Digital Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 28: Europe 7-Year Perspective for Digital Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 29: Europe Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 30: Europe 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 31: Europe Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 32: Europe 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • FRANCE
    • TABLE 33: France Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 34: France 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 35: France Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 36: France 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • GERMANY
    • TABLE 37: Germany Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 38: Germany 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 39: Germany Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 40: Germany 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • ITALY
    • TABLE 41: Italy Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 42: Italy 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 43: Italy Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 44: Italy 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 45: UK Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 46: UK 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 47: UK Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 48: UK 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 49: Rest of Europe Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 50: Rest of Europe 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 51: Rest of Europe Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 52: Rest of Europe 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 53: Asia-Pacific Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 54: Asia-Pacific 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 55: Asia-Pacific Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 56: Asia-Pacific 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 57: Rest of World Current & Future Analysis for Digital Therapeutics by Application - Preventive and Treatment/Care - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 58: Rest of World 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Sales for Preventive and Treatment/Care for the Years 2020 & 2027
    • TABLE 59: Rest of World Current & Future Analysis for Digital Therapeutics by Sales Channel - B2C and B2B - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 60: Rest of World 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for B2C and B2B for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 56